据估计,慢性肾脏病(Chronic Kidney Disease,CKD)影响全球约8.5亿人,到2040年,CKD预计将成为全球导致预期寿命缩短的第五大病因[1]。 糖尿病肾脏疾病(diabetic kidney disease,DKD)是一种由糖尿病引起的慢性肾脏病。DKD是引起终末期肾病...
近日,德克萨斯大学西南医学中心的研究人员在 Nature 子刊 Nature Communications 上发表了题为:Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease的研究论文。 该研究发现,与另一...
8.Rossing P, Agarwal R, Bakris GL, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial in patients with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(8):1626-1635 9.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, ...
8.Rossing P, Agarwal R, Bakris GL, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial in patients with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38(8):1626-1635 9.Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, ...
近日,德克萨斯大学西南医学中心的研究人员在 Nature 子刊 Nature Communications 上发表了题为:Healthcare utilization, mortality, and cardiovascular events following GLP1-RA initiation in chronic kidney disease 的研究论文。 该研究发现,与另一类常用的降糖药 DPP-4i 相比,胰高血糖素样肽-1 受体激动剂(GLP1-...
2024年10月,Henning Bliddal等研究学者在国际顶尖医学期刊The New England Journal of Medicine上发表了题为 Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis 的研究论文,为GLP-1受体激动剂开辟了新的治疗领域。这项由哥本哈根大学和诺和诺德公司合作开展的多中心研究首次证实了GLP-1受体激动剂...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as game-changers across the cardiovascular–kidney–metabolic (CKM) spectrum: overweight/obesity, type 2 diabetes mellitus (T2DM) and associated chronic kidney disease (CKD) and cardiovascular disease (CVD). Liraglu...
当1980年代科学家们首次发现GLP-1(胰高血糖素样肽-1)时,很少有人能预见这个分子将在未来彻底改变现代医学。从最初作为一个血糖调节因子为人所熟知,到如今,在糖尿病、心血管疾病、阿兹海默及抑郁症、肾病和肝脏疾病、关节炎等领域都有都有所作为,带来全方位地医疗突破,GLP-1已经成为近几年当之无愧最受全球瞩目...
1. Zhu D, et al. The prevalence and risk factors of chronic kidney disease in patients with type 2 diabetes in China: a cross-sectional study. Presented at American Diabetes Association 83th Scientific Sessions, Jun 23-26, 2023. 2. Perkovic V, et al. N Engl J Med. 2024; 391(2): ...
参考资料: 1.Could weight-loss drugs treat other chronic diseases? 2.Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease 3.Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling.